Brodalumab for Plaque Psoriasis: A Canadian Real-World Experience at 2-Years Post-Launch.
Veronique GaudetBelinda YapShazia HassanMartin BarbeauPublished in: Journal of cutaneous medicine and surgery (2023)
The effectiveness of brodalumab was demonstrated in this Canadian routine care study, with significant improvements in disease severity and patient-reported outcomes. High continuation rates were achieved; including in patients previously treated with IL-17A inhibitors. Future studies will provide further evidence of brodalumab's benefits for the management of plaque psoriasis in the real-world setting.
Keyphrases
- patient reported outcomes
- newly diagnosed
- end stage renal disease
- coronary artery disease
- healthcare
- ejection fraction
- randomized controlled trial
- palliative care
- systematic review
- chronic kidney disease
- clinical practice
- prognostic factors
- current status
- quality improvement
- atopic dermatitis
- pain management
- case control